Innovative Immunotherapy Company Expands Team

  • Atara Biotherapeutics grants restricted stock units to a newly hired employee
  • Employee vesting schedule over four years
  • First company in the world with allogeneic T-cell immunotherapy approval

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, has granted 3,500 restricted stock units of common stock to a newly hired employee. The grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and vests over four years, with 25% vesting on the first quarterly date after the anniversary and the remainder in 12 equal installments over three years. Atara Biotherapeutics is a pioneering company in off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, with cutting-edge science and a diverse portfolio of investigational therapies targeting Epstein-Barr virus. As the first to receive allogeneic T-cell immunotherapy approval, Atara is headquartered in Southern California.

Factuality Level: 10
Factuality Justification: The article provides accurate and objective information about Atara Biotherapeutics, its platform, and the grant of restricted stock units to a newly hired employee. It is relevant, concise, and free from sensationalism or personal perspective.
Noise Level: 2
Noise Justification: The article provides relevant information about a company’s stock grant to an employee and highlights the company’s work in T-cell immunotherapy for cancer and autoimmune diseases. It is informative without being noisy or irrelevant.
Public Companies: Atara Biotherapeutics, Inc. (ATRA)
Key People:

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: No
Financial Rating Justification: The article discusses the granting of restricted stock units to a newly hired employee at Atara Biotherapeutics, a company involved in T-cell immunotherapy. This is relevant to financial topics as it involves stock options and compensation for employees. However, there is no mention of any impact on specific financial markets or companies.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification:
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Neutral
Magnitude: No
Affected Instruments: Stocks

Reported publicly: www.businesswire.com